Georgia Howell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Georgia Howell has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Andrea L. Ludwig
Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina
11 shared publications - Annick Desjardins
The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, USA
11 shared publications - Darell Bigner
Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
11 shared publications - David M. Ashley
Duke University
11 shared publications - Dirk Peter Dittmer
Lineberger Comprehensive Cancer Center and Department of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill
11 shared publications - Griffin P. Carter
Department of Molecular Genetics & Microbiology, Duke University School of Medicine, Durham, NC 27710, USA
11 shared publications
Latest Publications
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Supplementary Table S3. Top-20 differentially expressed genes in tumor-infiltrating T cell subsets (extended data relating to Figure 5D).
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Supplementary Table S3. Top-20 differentially expressed genes in tumor-infiltrating T cell subsets (extended data relating to Figure 5D).
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Supplementary Figure S2. Differences in gene expression and hallmark pathways between single-site (IT or CPLI) and dual-site (IT plus CPLI) treatment cohorts compared to mock treatment as shown.
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Supplementary Figure S2. Differences in gene expression and hallmark pathways between single-site (IT or CPLI) and dual-site (IT plus CPLI) treatment cohorts compared to mock treatment as shown.
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Supplementary Figure S4. a,b, Extended data relating to Figure 4C-G. MECA-79+ HEV, which harbor (-)strand vRNA in CT2A glioma-bearing mice after dual site (IT+CPLI) PVSRIPO, stain positive for the poliovirus receptor CD155.
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Supplementary Figure S4. a,b, Extended data relating to Figure 4C-G. MECA-79+ HEV, which harbor (-)strand vRNA in CT2A glioma-bearing mice after dual site (IT+CPLI) PVSRIPO, stain positive for the poliovirus receptor CD155.
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Supplementary Figure S1. Extended data on cLN phenotypes after IT PVSRIPO infusion in CT2A mouse glioma.
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Supplementary Figure S1. Extended data on cLN phenotypes after IT PVSRIPO infusion in CT2A mouse glioma.
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Data from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Tumor-draining lymph nodes are a pivotal site for antitumor T-cell priming. However, their mechanistic roles in cancer immune surveillance and immunotherapy response remain poorly defined. Intratumor (IT) virotherapy generates antitumor T-cell immunity through multifaceted engagement of innate antiviral inflammation. In this study, we identify type-I interferon (IFNI) signaling in glioma-draining cervical lymph nodes as a mediator of IT polio virotherapy. Transient IFNI signaling after IT administration was rescued by cervical perilymphatic infusion (CPLI) virotherapy, targeting cervical lymph nodes directly. Dual-site (IT plus CPLI) virotherapy induced profound inflammatory reprogramming of cervical lymph nodes, enhanced viral RNA replication and IFNI signaling in dendritic cells and high endothelial venules, augmented antiglioma efficacy in mice, and was associated with T-cell activation in patients with recurrent glioblastoma. A phase II clinical trial of IT plus CPLI polio virotherapy is ongoing (NCT06177964). This study implicates the lymphatic system as a virotherapy target and demonstrates that CPLI virotherapy has the potential to complement brain tumor immunotherapy.See related Spotlight by Kaufman, p. 182
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Tumor-draining lymph nodes are a pivotal site for antitumor T-cell priming. However, their mechanistic roles in cancer immune surveillance and immunotherapy response remain poorly defined. Intratumor (IT) virotherapy generates antitumor T-cell immunity through multifaceted engagement of innate antiviral inflammation. In this study, we identify type-I interferon (IFNI) signaling in glioma-draining cervical lymph nodes as a mediator of IT polio virotherapy. Transient IFNI signaling after IT administration was rescued by cervical perilymphatic infusion (CPLI) virotherapy, targeting cervical lymph nodes directly. Dual-site (IT plus CPLI) virotherapy induced profound inflammatory reprogramming of cervical lymph nodes, enhanced viral RNA replication and IFNI signaling in dendritic cells and high endothelial venules, augmented antiglioma efficacy in mice, and was associated with T-cell activation in patients with recurrent glioblastoma. A phase II clinical trial of IT plus CPLI polio virotherapy is ongoing (NCT06177964). This study implicates the lymphatic system as a virotherapy target and demonstrates that CPLI virotherapy has the potential to complement brain tumor immunotherapy.See related Spotlight by Kaufman, p. 182
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Supplementary Figure S6. a-c, Extended data relating to Figure 5. Umap of snRNAseq of combined samples from three intervals (see Figure 5D); individual cell types are labeled (a). Umap of cells identified as T cells in a; individual subsets are labeled (see Supplementary Table S2 for extended data) (b). Proportion of cell types identified in a by time point (c). d, e, Gating strategy used (extended data relating to Figure 5E, F).
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Supplementary Figure S6. a-c, Extended data relating to Figure 5. Umap of snRNAseq of combined samples from three intervals (see Figure 5D); individual cell types are labeled (a). Umap of cells identified as T cells in a; individual subsets are labeled (see Supplementary Table S2 for extended data) (b). Proportion of cell types identified in a by time point (c). d, e, Gating strategy used (extended data relating to Figure 5E, F).
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Antibodies used in flow-cytometry analyses
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Antibodies used in flow-cytometry analyses
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Supplementary Figure S3. Dual-site (IT+CPLI) PVSRIPO in CT2A-bearing mice changes immune cell composition in cLN (extended data relating to Figure 3).
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Supplementary Figure S3. Dual-site (IT+CPLI) PVSRIPO in CT2A-bearing mice changes immune cell composition in cLN (extended data relating to Figure 3).
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Supplementary Table S2. FISH probe sets (extended data relating to Figures 2C, 4).
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Supplementary Table S2. FISH probe sets (extended data relating to Figures 2C, 4).
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Supplementary Figure S5. PVSRIPO is shed in phosphatidyl-serine enriched vesicles from A375 melanoma cells (extended data relating to Figure 4G).
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Supplementary Figure S5. PVSRIPO is shed in phosphatidyl-serine enriched vesicles from A375 melanoma cells (extended data relating to Figure 4G).